Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Mesoblast wins long-awaited approval for cell therapy

5 months ago

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

5 months ago

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

5 months ago

Exclusive: Cell therapy startup Shinobi adds Borges as science chief, Katz as top medical officer

5 months ago

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

5 months ago

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

5 months ago

Editas to cut 65% of workforce, officially stops work on ex vivo sickle cell therapy

5 months ago

Chroma, Nvelop merge to form nChroma Bio, raising $75M to enter the clinic

5 months ago

Arcellx and Gilead seek to unseat Legend and J&J with multiple myeloma cell therapy

5 months ago

Beam shares results from seven patients who received gene-edited sickle cell therapy

5 months ago

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

5 months ago

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

6 months ago

Patient dies in Neurogene's Rett syndrome study

6 months ago

Bristol Myers takes on autoimmune diseases with cell therapy, plus new data from Cabaletta and Kyverna

6 months ago

Rocket shares promising long-term results from rare heart disease gene therapy in small study

6 months ago

Neurogene patient had life-threatening side effect in Rett syndrome study

6 months ago

CSL Behring will close California office as part of shrinking ex vivo work

6 months ago

FDA offers more guidance on developing cell and gene therapies

6 months ago

Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis asset

6 months ago

Gilead will close Philadelphia, Seattle offices as part of job reductions

6 months ago

Arc Institute publishes new AI model Evo, creating CRISPR systems in a leap for synthetic biology

6 months ago

As bluebird projects more commercial demand, the biotech continues to seek cash

6 months ago

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

6 months ago

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

6 months ago

First page Previous page 1 2 345 6 7 Next page Last page